Daylight photodynamic therapy as a treatment for actinic field change in patients diagnosed with oculocutaneous albinism in sub-Saharan Africa.

Autor:	Twigg E; Department of Dermatology, University Hospitals of Leicester NHS Trust, Leicester, UK., Roberts E; Department of Dermatology, University Hospitals of Leicester NHS Trust, Leicester, UK., Sharp A; Department of Dermatology, University Hospitals of Leicester NHS Trust, Leicester, UK., Iraba J; Bugando Medical Centre, Mwanza, Tanzania., Chapa P; Dodoma Regional Referral Hospital, Dodoma, Tanzania., Freeland H; Regional Dermatology Training Centre, Moshi, Tanzania., Mavura D; Standing Voice, London, UK.
Jazyk:	angličtina
Zdroj:	Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Apr 23; Vol. 49 (5), pp. 484-490.
DOI:	10.1093/ced/llad406
Abstrakt:	Background: Oculocutaneous albinism (OCA) is a genetically inherited condition, whereby melanin is reduced or absent in the skin. A lack of melanin predisposes people to actinic damage and skin malignancies. In Tanzania, a resource-limited country, the treatment of choice for precancerous skin lesions is cryotherapy. Objectives: To investigate whether daylight photodynamic therapy (dPDT) is a safe and well-tolerated treatment for actinic field change in the OCA population in Tanzania. Methods: Twelve participants with actinic damage were recruited from a Standing Voice skin surveillance clinic and treated with dPDT. Study participants completed tolerability and acceptability questionnaires at day 5 and 3 months after treatment. A dermatologist assessed their clinical response to dPDT at 3 months. Results: dPDT was well-tolerated and acceptable to the majority of patients. Actinic damage was reduced by 25-90%. No skin cancers developed during the treatment. Conclusions: This pilot study suggests that dPDT is a safe and tolerable treatment for actinic damage in people with OCA in Tanzania. Further work is required to compare the efficacy of dPDT against other topical therapies for actinic field change. Competing Interests: Conflicts of interest A.S. is chair of the skin cancer advisory committee for Standing Voice. D.M. sits on the skin cancer advisory committee for Standing Voice. H.F. is executive director/founder of Standing Voice. The other authors declare no conflicts of interest. (© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu